(Q37897817)

English

Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis

scientific article published on 05 July 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

0 references

1 reference

Europe PubMed Central

Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis (English)

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

type 2 diabetes

0 references

0 references

systematic review

1 reference

based on heuristic

inferred from title

author name string

Nicole R Pinelli

1

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

Kathryn M Hurren

2

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

language of work or name

0 references

publication date

5 July 2011

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

Annals of Pharmacotherapy

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

45

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

7-8

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

850-860

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

Diabetes trends in the U.S.: 1990-1998.

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1Q024

21 January 2018

Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1Q024

21 January 2018

Diagnosis and classification of diabetes mellitus

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1Q024

21 January 2018

Prevalence and trends in obesity among US adults, 1999-2008

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1Q024

21 January 2018

Addressing the unmet medical need for safe and effective weight loss therapies

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1Q024

21 January 2018

Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM.

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1Q024

21 January 2018

Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1Q024

21 January 2018

Glucagon-like peptides

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1Q024

21 January 2018

Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1Q024

21 January 2018

Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1Q024

21 January 2018

Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1Q024

21 January 2018

Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1Q024

21 January 2018

Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1Q024

21 January 2018

Quantifying heterogeneity in a meta-analysis

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1Q024

21 January 2018

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1Q024

21 January 2018

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1Q024

21 January 2018

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1Q024

21 January 2018

Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1Q024

21 January 2018

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1Q024

21 January 2018

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1Q024

21 January 2018

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1Q024

21 January 2018

Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1Q024

21 January 2018

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1Q024

21 January 2018

The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men.

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1Q024

21 January 2018

Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1Q024

21 January 2018

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1Q024

21 January 2018

Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1Q024

21 January 2018

Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1Q024

21 January 2018

Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men.

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1Q024

21 January 2018

Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease.

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1Q024

21 January 2018

Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1Q024

21 January 2018

DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1Q024

21 January 2018

Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1Q024

21 January 2018

Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1Q024

21 January 2018

Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1Q024

21 January 2018

The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1-5 studies

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1Q024

21 January 2018

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1Q024

21 January 2018

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1Q024

21 January 2018

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1Q024

21 January 2018

Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1Q024

21 January 2018

Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1Q024

21 January 2018

Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation.

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1Q024

21 January 2018

Glucagon-like peptide-1 reduces hepatic glucose production indirectly through insulin and glucagon in humans

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1Q024

21 January 2018

Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1Q024

21 January 2018

Identifiers

10.1345/APH.1Q024

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37897817&oldid=2099316034"